| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO and President | See Remarks +1 more
1 company
Eric D. Shaff is Director at MCRB. Eric D. Shaff's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $24K at current prices.
Our model assigns Eric D. Shaff a middling insider score of 69/100, based on 12 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +15.0%.
The MCRB filings lean toward selling, a net 86,864 shares.
Eric D. Shaff has 31 Form 4 filings on record from June 2015 to August 2026, all as Director at Seres Therapeutics (MCRB), 2015–2026.
The 66 reported transactions were 26 option exercises, 22 open-market sales, 17 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 20 sales worth about $914K.
The largest open-market sale was 7,663 shares of MCRB at an average $26.30 on March 31, 2016, about $202K.
All 13 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | MCRB Seres Therapeutics, Inc. | Director | Sale+OE10b5-1 | 263 | $4.55 | $1,196.65 | -2.1% | - | - | |
| May 18, 2026 | MCRB Seres Therapeutics, Inc. | Director | Sale+OE10b5-1 | 259 | $7.53 | $1,950.27 | -2.1% | -40.6% | - | |
| Feb 15, 2026 | MCRB Seres Therapeutics, Inc. | Director | Sale+OE10b5-1 | 259 | $8.47 | $2,193.73 | -2.2% | -7.7% | - | |
| Nov 15, 2025 | MCRB Seres Therapeutics, Inc. | Director | Sale+OE10b5-1 | 217 | $17.30 | $3,754.10 | -1.9% | -49.2% | - | |
| Aug 18, 2025 | MCRB Seres Therapeutics, Inc. | Director | Sale+OE10b5-1 | 217 | $16.65 | $3,613.05 | -2.0% | +22.3% | -75.5% | |
| May 16, 2025 | MCRB Seres Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 220 | $7.28 | $1,601.60 | -2.1% | +126.0% | +2.4% | |
| Feb 18, 2025 | MCRB Seres Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 12,726 | $0.81 | $10,314.42 | -6.2% | -52.0% | -50.5% | |
| Nov 18, 2024 | MCRB Seres Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 2,505 | $0.54 | $1,354.95 | -1.4% | +43.6% | +113.4% | |
| Oct 28, 2024 | MCRB Seres Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 8,748 | $0.69 | $6,036.99 | -5.0% | +20.2% | +22.6% | |
| Aug 16, 2024 | MCRB Seres Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 2,518 | $0.84 | $2,115.12 | -1.7% | -32.7% | -5.1% |